
    
      Overall study design

        -  This is a single arm phase IIa study of convalescent plasma for the treatment of
           individuals hospitalized with COVID-19 infection.

        -  Subjects will be considered as having completed the study after 60 (+/- 3) days, unless
           consent withdrawal or death occurs first.

        -  Interim analysis will be permitted as described in the statistical section 8.

        -  The final analysis will be conducted once the last subject completes the day 60 visit or
           withdraws from the study.

      Number of subjects

      â€¢ Up to 36 patients in track 2, and 19 patients in track 3 as described in the statistical
      section 8.

      Overall study duration

        -  The study begins when the first subject (this will likely be a donor) signs the informed
           consent. The study will end once the last enrolled subject completes the study (likely a
           recipient).

        -  The expected duration of the study is approximately 12 months.
    
  